Completed PHASE1 INTERVENTIONAL 1-arm NCT00592046

A Phase I Trial of ZIO-101 in Hematologic Cancers

Sponsor: Alaunos Therapeutics

Conditions Acute Leukemia Chronic Lymphoproliferative Disease Chronic Myeloproliferative Disease Lymphoma Multiple Myeloma Poor-risk Myelodysplasia (MDS)

Interventions ZIO-101 (Darinaparsin)

Updated 7 times since 2017 Last updated: Jul 18, 2012 Started: May 31, 2005 Primary completion: Jun 30, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00592046, this PHASE1 trial focuses on Acute Leukemia and Chronic Lymphoproliferative Disease and remains completed. Sponsored by Alaunos Therapeutics, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alaunos Therapeutics

Data source: Alaunos Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States